Therapy for ankylosing spondylitis: New treatment modalities

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 4, 2002, Pages 631-651

  Braun, J ^a   Breban, Maxime ^b   Maksymowych, Walter P ^c  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b Hôpital Cochin ^*  (France)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biological agents; Etanercept; Infliximab; Outcome parameters; Spondyloarthritides

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; ETANERCEPT; GAMMA INTERFERON; HLA B27 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; ISONIAZID; METHOTREXATE; METRONIDAZOLE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; RADIUM 224; RECOMBINANT INTERLEUKIN 11; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; CYTOKINE RECEPTOR ANTAGONIST; ENZYME INHIBITOR; L N6 (L IMINOETHYL)LYSINE; RECOMBINANT INTERLEUKIN 10; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; AUTOIMMUNE DISEASE; BACKACHE; BACTERIAL INFECTION; BIRTH DEFECT; CLINICAL TRIAL; CONSTIPATION; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DROWSINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EUROPE; HEART FAILURE; HUMAN; LEUKOPENIA; LIMB MALFORMATION; LONG TERM CARE; LUNG GRANULOMATOSIS; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MICROFLORA; MYALGIA; NEUROPATHY; NONHUMAN; OUTCOMES RESEARCH; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; TITRIMETRY; TUBERCULOSIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; ALLERGIC REACTION; APHERESIS; COLITIS; CROHN DISEASE; DIZZINESS; DOSE RESPONSE; DRUG INHIBITION; ENTERITIS; ERYTHEMA NODOSUM LEPROSUM; FEVER; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; IRIDOCYCLITIS; PHOCOMELIA; RESPIRATORY TRACT INFECTION; SQUAMOUS CELL CARCINOMA; BIOLOGICAL THERAPY; METHODOLOGY; THERAPY;

ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; HUMANS; SPONDYLITIS, ANKYLOSING; THERAPEUTICS;

EID: 0036731162     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(02)90245-7     Document Type: Review

References (130)

1. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis & Rheumatism 1998; 41: 58-67.
2. Brandt J, Bollow M, Haberle J et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: Many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999; 38: 831-836.
3. Van Der Linden SM, Valkenburg HA, De Jongh BM & Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis & Rheumatism 1984; 27: 241-249.
4. Gran JT, Husby G & Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Annals of the Rheumatic Diseases 1985; 44: 359-367.
5. Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. Journal of Rheumatology 1999; 26: 2622-2627.
6. Zink A, Braun J, Listing J & Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - Results from the German rheumatological database. German Collaborative Arthritis Centers. Journal of Rheumatology 2000; 27: 613-622.
7. Ward MM. Health-related quality of life in ankylosing spondylitis: A survey of 175 patients. Arthritis Care Research 1999; 12: 247-255.
8. Zink A, Listing J, Klindworth C & Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Annals of the Rheumatic Diseases 2001; 60: 199-206.
9. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis & Rheumatism 2000; 43: 1346-1352.
10. Boonen A, Chorus A, Miedema H et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients. Annals of the Rheumatic Diseases 2001; 60: 353-358.
11. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis & Rheumatism 1993; 36: 1681-1690.
12. Maini RN, Elliott MJ, Brennan FM et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunological Reviews 1995; 144: 195-223.
13. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 1999; 130: 478-486.
14. Braun J & Sieper J. The sacroiliac joint in the spondyloarthropathies. Current Opinion in Rheumatology 1996; 8: 250-262.
15. Francois RJ, Gardner DL, Degrave EJ & Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis & Rheumatism 2000; 43: 2011-2024.
16. Braun J, Sieper J & Bollow M. Imaging of sacroiliitis. Clinical Rheumatology 2000; 19: 51-57.
17. McGonagle D, Gibbon W, O'Connor P et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis & Rheumatism 1998; 41: 694-700.
18. Braun J, Khan MA & Sieper J. Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response? Annals of the Rheumatic Diseases 2000; 59: 985-994.
19. Laloux L, Voisin MC, Allain J et al. Immunohistological study of entheses in spondyloarthropathies: Comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases 2001; 60: 316-321.
20. Braun J, Bollow M, Eggens U et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis & Rheumatism 1994; 37: 1039-1045.
21. Braun J, Bollow M & Sieper J. Radiology and pathology of the spondyloarthropathies. Rheumatic Disease Clinics of North America 1998; 24: 697-735.
22. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis & Rheumatism 1995; 38: 499-505.
23. Bollow M, Fischer T, Reißhauer H et al. T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Annals of the Rheumatic Diseases 2000; 59: 135-140.
24. Mielants H, Veys EM, Goemaere S et al. A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. Journal of Rheumatology 1993; 20: 1353-1358.
25. Mielants H & Veys EM. HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis. Journal of Rheumatology 1985; 12: 287-293.
26. Sandborn WJ. Anti-tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety. Inflammatory Bowel Diseases 1999; 5: 119-133.
27. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
28. Van Den Bosch F, Kruithof E, De Vos M et al. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-1822.
29. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-390.
30. Antoni C, Dechant C, Lorenz HM et al. Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Research 2002 (in press).
31. Garrett S, Jenkinson TR, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. Journal of Rheumatology 1994; 21: 2286-2291.
32. Brandt J, Haibel H, Reddig J et al. Treatment of patients with severe ankylosing spondylitis with infliximab - A one year follow up. Arthritis & Rheumatism 2001; 44: 2936-2937.
33. Van Den Bosch F, Kruithof E, Baeten D et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondylarthropathy: An open pilot study. Annals of the Rheumatic Diseases 2000; 59: 428-433.
34. Stone M, Salonen D, Lax M et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. Journal of Rheumatology 2001; 28: 1605-1614.
35. Collantes E, Munoz-Villanueva MC, Sanmarti R et al. Infliximab in Refractory Spondyloarthropathies, Preliminary Results in Spanish Population. Abstr. No 1049, EULAR, June, 2001.
36. Breban MA, Vignon E, Claudepierre P et al. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of an open label study. Annual European Congress on Rheumatology, European League Against Rheumatism, EULAR, Prague, Czech Republic, June 13-16, 2001, Abstr No. OP0058.
37. Allali F, Roux C, Kolta S et al. Infliximab in the treatment of spondylarthropathy, bone mineral density effect. Arthritis & Rheumatism 2001; 44: S89.
38. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab - A double-blind placebo controlled multicenter trial. Lancet 2002; 359: 1187-1193.
39. Brandt J, Haibel H, Reddig J et al. Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. Journal of Rheumatology 2002; 29: 118-122.
40. Marzo-Ortega H, McGonagle D, O'Connor P & Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. Arthritis & Rheumatism 2001; 44: 2112-2117.
41. Gorman JD, Sack KE & Davis JC. Etanercept in the treatment of ankylosing spondylitis: A randomized, double-blind, placebo-controlled study. Arthritis & Rheumatism 2000; 43: S403.
42. Smith JR, Levinson RD, Holland GN et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism 2001; 45: 252-257.
43. El-Shabrawi Y & Hermann J. Anti-TNFa therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis - A one year follow up. Arthritis & Rheumatism 2001; 44: S425.
44. Lipsky PE, Van Der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine 2000; 343: 1594-1602.
45. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine 2001; 11: 1098-1104.
46. Canete JD, Martinez SE, Farres J et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon-γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases 2000; 59: 263-268.
47. Claudepierre P, Rymer JC & Chevalier X. IL-10 plasma levels correlate with disease activity in spondyloarthropathy. Journal of Rheumatology 1997; 24: 1659-1661.
48. Yin Z, Braun J, Neure L et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis & Rheumatism 1997; 40: 1788-1799.
49. Yin Z, Siegert S, Neure L et al. The elevated ratio of interferon-γ/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology 1999; 38: 1058-1067.
50. Braun J, Yin Z, Spiller I et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis & Rheumatism 1999; 42: 2039-2044.
51. Rudwaleit M, Siegert S, Yin Z et al. Low T cell production of TNF-α and IFN-γ in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Annals of the Rheumatic Diseases 2001; 60: 36-42.
52. Braun J, Xiang J, Brandt J et al. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: First clinical and laboratory experiences. Annals of the Rheumatic Diseases 2000; 59 (supplement 1): 10-14.
53. Baeten D, Van Damme N, Van Den Bosch F et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases 2001; 60: 750-755.
54. Baeten D, Kruithof E, Van Den Bosch F et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis & Rheumatism 2001; 44: 186-195.
55. Xiang J, Rudwaleit M, Thiel A et al. Downregulation of the nonspecific and the antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab. Arthritis & Rheumatism 2001; 44: S236.
56. Ueo T, Kobori K, Okumura H et al. Effectiveness of lymphocytapheresis in a patient with ankylosing spondylitis. Transfusion Science 1990; 11: 97-101.
57. Jantunen E, Myllykangas-Luosujarvi R, Kaipiainen-Seppanen O & Nousiainen T. Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 2001; 39: 563-564.
58. Koch B, Kranzhofer N, Pfreundschuh M et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant 2000; 26: 673-675.
59. 2m: An animal model of HLA-B27-associated human disorders. Cell 1990; 63: 1099-1112.
60. Taurog JD, Maika S, Satumtira N et al. Inflammatory disease in HLA-B27 transgenic rats. Immunological Reviews 1995; 169: 209-223.
61. Breban M, Fernandez-Sueiro JL, Richardson JA et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. Journal of Immunology 1996; 156: 794-803.
62. Rath HC, Bender DE, Holt LC et al. Metronidazole attenuates colitis in HLA-B27/hB2 microglobulin transgenic rats: A pathogenic role for anaerobic bacteria. Clinical Immunology and Immunopathology 1995; 76: S45.
63. 2 microglobulin transgenic rats. Journal of Clinical Investigation 1996; 98: 945-953.
64. Aiko S & Grisham MB. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology 1995; 109: 142-150.
65. Blanchard HS, Dernis-Labous E, Lamarque D et al. Inducible nitric oxide synthase attenuates chronic colitis in HLA-B27/human 2-microglobulin transgenic rats. European Cytokine Network 2001; 12: 111-118.
66. Bertrand V, Quere S, Guimbaud R et al. Effects of murine recombinant IL-10 on the inflammatory disease of rats transgenic for HLA-B27 and human 2-microglobulin. European Cytokine Network 1998; 9: 161-170.
67. Peterson RL, Wang L, Albert L et al. Molecular effects of recombinant human interleukin-II in the HLA-B27 rat model of inflammatory bowel disease. Laboratory Investigation 1998; 78: 1503-1512.
68. Calabrese L & Fleischer AB. Thalidomide: Current and potential clinical applications. American Journal of Medicine 2000; 108: 487-495.
69. Bekker L-G, Haslett P, Maartens G et al. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. Journal of Infectious Diseases 2000; 181: 954-965.
70. Haslett PA, Corral LG, Albert M & Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine 1998; 187: 1885-1892.
71. D'Amato RJ, Loughman MS, Flynn E & Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the USA 1994; 91: 4082-4085.
72. Keifer JA, Guttridge DC, Ashburner BP & Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. Journal of Biological Chemistry 2001; 276: 22 382-22 387.
73. Breban M, Gombert B, Amor B & Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis and Rheumatism 1999; 42: 580-581.
74. Breban M & Dougados M. The efficacy of thalidomide in severe refractory seronegative spondyloarthropathy: Comment on the letter by Breban et al. Reply. Arthritis and Rheumatism 2001; 44: 2457-2458.
75. El Hassani S, Dougados M, Gombert B et al. Treatment of severe refractory spondylarthropathy (SPA) with thalidomide: Results of an open study. Arthritis and Rheumatism 1998; 1999; 42: S373.
76. Lee L, Lawford R & McNeil P. The efficacy of thalidomide in severe seronegative spondyloarthropathy. Arthritis and Rheumatism 2001; 44: 2456-2457.
77. Huang F, Gu J, Braun J & Yu D. Identifying the targets of thalidomide and anti-TNFα antibody treatments in ankylosing spondylitis. Arthritis and Rheumatism 2000; 43: S396.
78. Huang F, Gu J, Zhao W et al. A one year open label trial of thalidomide in ankylosing spondylitis. Arthritis and Rheumatism (Arthritis Care and Research) 2002; 47 (in press).
79. Ginsburg PM, Dassopoulus T & Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: A review of the history, pharmacological mechanism and clinical literature. Annals of Medicine 2001; 33: 516-525.
80. Marriott JB, Muller G & Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunology Today 1999; 20: 538-540.
81. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.
82. Olivier SJ, Moreira A & Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clinical Immunology 2000; 97: 109-120.
83. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999; 163: 380-386.
84. Gratacos J, Collado A, Pons F et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow up study. Arthritis & Rheumatism 1999; 42: 2319-2324.
85. Poole AR. The histopathology of ankylosing spondylitis: Are there unifying hypotheses? American Journal of Medical Science 1998; 316: 228-233.
86. Smyth CJ & Freyberg RH. Roentgen therapy for rheumatoid arthritis of the spine. Journal of the American Medical Association 1941; 117: 826-830.
87. Wilkinson M & Bywaters EGL. Clinical features and course of ankylosing spondylitis as seen in a follow up of 222 hospital-referred cases. Annals of the Rheumatic Diseases 1958; 17: 209-228.
88. Desmarais MHL. Radiotherapy in arthritis. Annals of the Rheumatic Diseases 1953; 12: 25-28.
89. Weiss HA, Darby SC & Doll R. Cancer mortality following X-ray treatment of ankylosing spondylitis. International Journal of Cancer 1994; 59: 327-338.
90. Weiss HA, Darby SC, Fearn T & Doll R. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiation Research 1995; 142: 1-11.
91. 224Ra. Health Physics 1983; 44 (supplement 1): 197-202.
92. Braun J, Lemmel M, Manger B et al. Therapy of ankylosing spondylitis with Radiumchloride. Zeitschrift fues Rheumatologie 2001; 60: 74-83.
93. Wick RR, Nekolla EA, Gossner W & Kellerer AM. Late effects in ankylosing spondylitis patients treated with 224Ra. Radiation Research 1999; 152 (6 supplement): S8-S11.
94. Yates AJP, Percival RC, Gray RES et al. Intravenous clodronate in treatment and retreatment of Paget's disease of bone. Lancet 1985; i: 1474-1477.
95. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine 1996; 335: 1785-1791.
96. Chapurlat Rd, Delmas PD, Liens D & Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Journal of Bone and Mineral Research 1997; 12: 1746-1752.
97. Bijvoet OLM, Frijlink WB, Jie K et al. APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis & Rheumatism 1980; 23: 1193-1204.
98. Cecchini MG, Felix R, Fleisch H & Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research 1987; 2: 135-142.
99. Sansoni P, Passeri G, Fagnoni F et al. Inhibition of antigen-presenting cell function by alendronate in vitro. Journal of Bone and Mineral Research 1995; 10: 1719-1725.
100. Stevenson PH & Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcified Tissue International 1986; 38: 227-233.
101. Monkkonen J, Simila J & Rogers MJ. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sciences 1998; 62: 95-102.
102. Pennanen N, Lapinjoki S, Urti A & Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharmaceutical Research 1995; 12: 916-922.
103. Leyvraz S, Hess U, Flesch G et al. Pharmacokinetics of pamidronate in patients with bone metastases. Journal of the National Cancer Institute 1992; 84: 788-792.
104. Sato M & Graser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. Journal of Bone and Mineral Research 1990; 5: 31-40.
105. Van Beek E, Pieterman E, Cohen L et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochemical and Biophysical Research Communications 1999; 264: 108-111.
106. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 1998; 13: 581-586.
107. Khwaja A, Connolly JO & Hendry BM. Prenylation inhibitors in renal disease. Lancet 2000; 355: 741-744.
108. Dunn CJ, Doyle DV & Willoughby DA. Investigation of the acute and chronic anti-inflammatory properties of diphosphonates using a broad spectrum of immune and non-immune inflammatory reactions. Drug Development Research 1993; 28: 47-55.
109. Barbier A, Breliere JC, Remandet B & Roncucci R. Studies on the chronic phase of adjuvant arthritis: Effect of SR 41319, a new diphosphonate. Annals of the Rheumatic Diseases 1986; 45: 67-74.
110. Francis MD, Hovancik K & Boyce RW. NE-58095: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. International Journal of Tissue Reactions 1989; 11: 239-252.
111. Markusse HM, Lafeber GJM & Breedveld FC. Bisphosphonates in collagen arthritis. Rheumatology International 1990; 9: 281-283.
112. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcified Tissue International 1987; 41: 326-331.
113. Pietschmann P, Stohlawetz P, Brosch S et al. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration. Calcified Tissue International 1998; 63: 325-330.
114. Kunzmann V, Bauer E & Wilhelm M. γ/δ T-cell stimulation by pamidronate. New England Journal of Medicine 1999; 340: 737-738.
115. Cantatore FP, Acquista CA & Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. Journal of Rheumatology 1999; 26: 2318-2323.
116. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88: 1082-1090.
117. Varenna M, Zucchi F, Binelli L et al. Intravenous pamidronate in the treatment of bone marrow edema syndrome. Journal of Bone and Mineral Research 2002 (in press).
118. Maksymowych WP, Jhangri GS, LeClercq S et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. Journal of Rheumatology 1998; 25: 714-717.
119. Maksymowych WP, Lambert R, Jhangri GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. Journal of Rheumatology 2001; 28: 144-155.
120. Jenkinson TR, Mallorie PA, Whitelock HC et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS metrology index. Journal of Rheumatology 1994; 21: 1694-1698.
121. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology 1994; 21: 2281-2285.
122. Maksymowych WP, Fitzgerald A, LeClercq S et al. A 6 month randomized double-blinded dose response comparison of i.v. pamidronate (60 mg vs 10 mg) in the treatment of NSAID-refractory ankylosing spondylitis. Arthritis & Rheumatism 2002; 46: 766-773.
123. Anderson JJ, Baron G, Van Der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis & Rheumatism 2001; 44: 1876-1886.
124. Maksymowych WP. Ankylosing spondylitis - At the interface of cartilage and bone. Journal of Rheumatology 2000; 27: 2295-2301.
125. Cooper C, Carbone L, Michet CJ et al. Fracture risk in patients with ankylosing spondylitis: A population based study. Journal of Rheumatology 1994; 21: 1877-1882.
126. Van Der Heijde D, Bellamy N, Calin A et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. Journal of Rheumatology 1997; 24: 2225-2229.
127. MacKay K, Mack C, Brophy S & Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): A new, validated approach to disease assessment. Arthritis & Rheumatism 1998; 41: 2263-2270.
128. Spoorenberg A, De Vlam K, Van Der Heijde D et al. Radiologic scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year. Journal of Rheumatology 1999; 26: 997-1002.
129. Averns HL, Oxtoby J, Taylor HG et al. Radiological outcome in ankylosing spondylitis: Use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). British Journal of Rheumatology 1996; 35: 373-376.
130. Van Tubergen A, Landewe R & Van Der Heijde D. Combined Spa-exercise therapy is effective in patients with ankylosing spondylitis: A randomized controlled trial. Arthritis & Rheumatism 2001; 45: 430-438.